Trevi Therapeutics, Inc. - Common Stock (TRVI)
15.31
+0.00 (0.00%)
NASDAQ · Last Trade: Nov 10th, 5:30 AM EST
News & Press Releases
Trevi Therapeutics (TRVI) Q3 2026 Earnings Call Transcriptfool.com
Cash runway now reaches 2030 as key trial timelines come into focus.
Via The Motley Fool · November 10, 2026
What Trevi Therapeutics (TRVI) Said on Its Q3 Earnings Callmarketbeat.com
Trevi Therapeutics (NASDAQ:TRVI) said it remains on track to report results from its lead chronic cough trials in 2027 and 2028, while preparing a new study in patients with interstitial lung disease other than idiopathic pulmonary fibrosis.
On its third-quarter 2026 earnings call, the company also
Via MarketBeat · November 9, 2026
Trevi Therapeutics Q2 Earnings Call Highlightsmarketbeat.com
Trevi Therapeutics (NASDAQ:TRVI) said it began two clinical trials during the second quarter and plans to launch a third study in the third quarter as it advances nalbuphine ER, also known as Haduvio, for multiple chronic-cough indications.
President and Chief Executive Officer Jennifer Good said t
Via MarketBeat · August 7, 2026
Trevi Therapeutics Inc. (NASDAQ:TRVI) Beats Q4 2025 EPS Estimates, Gains FDA Alignment for Phase 3 Programchartmill.com
Via Chartmill · March 17, 2026
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.fool.com
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.
Via The Motley Fool · June 3, 2026
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030marketbeat.com
Trevi Therapeutics (NASDAQ:TRVI) outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming clinical trial starts, a specialty commercial strategy and an extended cash runway following a recent fi
Via MarketBeat · May 9, 2026
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?fool.com
This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.
Via The Motley Fool · March 23, 2026
Trevi Therapeutics (TRVI) Earnings Transcriptfool.com
Trevi Therapeutics (TRVI) Earnings Transcript
Via The Motley Fool · March 18, 2026
TRVI Stock Slips After Company Plans Parallel Trials In Lung Disease — Stifel Dismisses Timeline Concernsstocktwits.com
The company announced its decision following a meeting with the U.S. Food and Drug Administration.
Via Stocktwits · March 9, 2026
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestonesfool.com
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.
Via The Motley Fool · December 3, 2025
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crashfool.com
A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.
Via The Motley Fool · November 28, 2025
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crashfool.com
A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.
Via The Motley Fool · November 27, 2025
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestonesfool.com
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.
Via The Motley Fool · November 27, 2025
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Yearfool.com
Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.
Via The Motley Fool · November 27, 2025
Trevi Therapeutics Inc (NASDAQ:TRVI) Reports Q3 2025 Results, Narrows Loss and Outlines Phase 3 Planschartmill.com
Trevi Therapeutics reported a narrower-than-expected Q3 2025 loss. The biopharma firm is preparing its Phase 3 program for Haduvio and has cash into 2028.
Via Chartmill · November 13, 2025
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga.com
Via Benzinga · October 3, 2025
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · September 9, 2025
This Adient Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursdaybenzinga.com
Via Benzinga · August 21, 2025
Dow Gains Over 100 Points; US Job Openings Increase In Aprilbenzinga.com
Via Benzinga · June 3, 2025
Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patientsbenzinga.com
Trevi's Haduvio met its primary endpoint in a Phase 2b trial for IPF-related chronic cough, with statistically significant results at multiple doses.
Via Benzinga · June 2, 2025